"However, patients with AMD do not undergo spontaneous remission. If AMD patients in a clinical trial experience improved vision during a clinical trial, the improvement can be almost certainly be attributed to the therapy.
There is no question that Squalamine works in AMD. What remains in doubt is how long the effect lasts (which dictates how often patients should be retreated) and what is the best dose to balance safety and efficacy."
I think you make a good points and this discussion is well worth the time. Are these new arguements that you overlooked when you had more trust over management such as in the post above?
It seems to me that you are not only questioning management but also the Dr's running the mexico trial as it was would not have been Levit that picked these patients. We have talked alot in the past about how the dr's in charge of those trials where some of the top dr's in their field. Has this changed?
Market Data 
Markets 
AI
